A randomized clinical study of capecitabine plus oxaliplatin compared with fluorouracil/leucovorin plus oxaliplatin in the treatment of advanced gastric cancer
- VernacularTitle:卡培他滨与氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗晚期胃癌的随机对照临床研究
- Author:
Shaojun CHEN
;
Haixin HUANG
;
Guisheng LI
- Publication Type:Journal Article
- Keywords:
capecitabine;
oxaliplatin;
fluorouracil;
leucovorin;
advanced gastric cancer
- From:
China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05)。The median time to progression (mTTP)was 5.8 months in XELOX group and 5.7 months in FOLFOX4 group. The median survival time (MST) was 10.0 months in XELOX group and 9.8 months in FOLFOX4 group, The toxicities were well tolerated,The incidence of grade Ⅲ+Ⅳ nausea and vomiting was significantly lower in XELOX group than in FOLFOX4 group (P0.05).Conclusions:Both of the two regimens were feasible, well tolerated and effective in treatment of advanced gastric cancer。XELOX regimen may be safer than FOLFOX4 regimen,especially in elderly patients or patients with ECOG PS of 1 to 2.
